MYC and hepatocellular carcinoma: This study, started in Apr 2014, was immediately followed by the subsequent phase I/II clinical trial (NCT 02314052, 2014, “Phase 1b/2, Multicenter, Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose and Recommended Phase 2 Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients With Hepatocellular Carcinoma (HCC)”).